Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment
Open Access
- 5 March 2019
- Vol. 11 (3), 317
- https://doi.org/10.3390/cancers11030317
Abstract
Tumor formation and growth depend on various biological metabolism processes that are distinctly different with normal tissues. Abnormal energy metabolism is one of the typical characteristics of tumors. It has been proven that most tumor cells highly rely on aerobic glycolysis to obtain energy rather than mitochondrial oxidative phosphorylation (OXPHOS) even in the presence of oxygen, a phenomenon called “Warburg effect”. Thus, inhibition of aerobic glycolysis becomes an attractive strategy to specifically kill tumor cells, while normal cells remain unaffected. In recent years, a small molecule alkylating agent, 3-bromopyruvate (3-BrPA), being an effective glycolytic inhibitor, has shown great potential as a promising antitumor drug. Not only it targets glycolysis process, but also inhibits mitochondrial OXPHOS in tumor cells. Excellent antitumor effects of 3-BrPA were observed in cultured cells and tumor-bearing animal models. In this review, we described the energy metabolic pathways of tumor cells, mechanism of action and cellular targets of 3-BrPA, antitumor effects, and the underlying mechanism of 3-BrPA alone or in combination with other antitumor drugs (e.g., cisplatin, doxorubicin, daunorubicin, 5-fluorouracil, etc.) in vitro and in vivo. In addition, few human case studies of 3-BrPA were also involved. Finally, the novel chemotherapeutic strategies of 3-BrPA, including wafer, liposomal nanoparticle, aerosol, and conjugate formulations, were also discussed for future clinical application.Keywords
Funding Information
- Beijing Natural Science Foundation (7184192, 7162015)
- Natural Science Foundation of China (21778011)
- China Postdoctoral Science Foundation funded project (No. 2017M620567, No. 2018ZZ-01-25, No. CIT&TCD20180308, No. PXM2015_014204_500175)
- Beijing Postdoctoral Research Foundation (No. 2018-ZZ-022)
This publication has 134 references indexed in Scilit:
- The Expression of Glyceraldehyde-3-Phosphate Dehydrogenase Associated Cell Cycle (GACC) Genes Correlates with Cancer Stage and Poor Survival in Patients with Solid TumorsPLOS ONE, 2013
- Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl EsterJournal of Bioenergetics and Biomembranes, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The diverse functions of GAPDH: Views from different subcellular compartmentsCellular Signalling, 2011
- Human pyruvate kinase M2: A multifunctional proteinProtein Science, 2010
- Identification of small molecule inhibitors of pyruvate kinase M2Biochemical Pharmacology, 2010
- Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3‐bromopyruvateCancer, 2009
- Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvateBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapySeminars in Cancer Biology, 2008
- Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaOncogene, 2006